Santiago Lopez
Pediatric Infectious Diseases · Sioux Falls, SDNPI 1922351246
Payments from drug & device makers
Across 154 payments — averaging $3980.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$562K
- GSK$19K
- Astrazeneca UK Limited$11K
- Merck$11K
- Modernatx, Inc.$5K
- Seqirus USA Inc$4K
- plus $27 from 2 others
What the payments were for
- Speaking & faculty fees$4,00032%
- Travel & lodging$8,13065%
- Food & beverage$2882%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 113 | $561,953 |
| GSK | 15 | $19,398 |
| Astrazeneca UK Limited | 4 | $11,474 |
| Merck | 11 | $10,845 |
| Modernatx, Inc. | 6 | $5,350 |
| Seqirus USA Inc | 3 | $4,000 |
| Novo Nordisk | 1 | $14 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZERBAXA$8,130
How this compares
Too few pediatric infectious diseases providers in South Dakotato place this figure against a meaningful peer group, so we don't.
Other pediatric infectious diseases in Sioux Falls
- Archana ChatterjeeSioux Falls$347K
- Margaret FreeSioux Falls$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.